Bernard Arnault is outpacing Elon Musk and Mark Zuckerberg in wealth gain this year after signs of a rebound in luxury demand boosted LVMH stock.
LVMH has reclaimed its spot as the biggest company in Europe, overtaking Novo Nordisk after a significant drop in the drugmaker's shares. The cause? Concerns that the US governmen
US tech titans Elon Musk, Mark Zuckerberg and Jeff Bezos are taking a prominent place in the new Trump era, but another player from another era -- Oracle boss Larry Ellison -- is making a surprise return.
Billionaire Larry Ellison’s backing of Stargate — a landmark, $500 billion artificial intelligence infrastructure project touted by President Trump — could help grease the wheels for the ...
The net worth of the six richest people in the crowd at Donald Trump's inauguration is roughly equal to a third of the value of the entire UK economy.
The LVMH CEO is now the world's fourth richest ... He leapfrogged Oracle cofounder Larry Ellison on Thursday to take fourth place on Bloomberg's rich list with an estimated $190 billion fortune ...
Feeling burned by the holdover of Obama administration appointees during his first go-around, Trump swiftly exiled Biden holdovers and moved to test new hires for their fealty to his agenda.
An investor group is mounting an eleventh-hour $13.5 billion offer for Paramount, claiming it is superior to the Larry Ellison-backed Skydance deal.
Larry, let’s negotiate in front of the media,” Trump said at a press conference with the Oracle co-founder, SoftBank CEO Masa Son, and OpenAI CEO Sam Altman to announce a $500 billion artificial intelligence infrastructure investment.
Earlier this month, Bloomberg reported that China was considering a TikTok sale to Elon Musk, the world's richest man and a close ally of President Trump, who already owns the social media platform X.
Robby Soave and Niall Stanage weigh in on debate of using A.I. to develop mRNA vaccines to target cancer. #AI #mrnavaccines
MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to represent a sustainable long-term revenue generator.